07:00 , Sep 17, 2015 |  BC Innovations  |  Finance

NIAAA focuses on developing medicines

NIH's National Institute on Alcohol Abuse and Alcoholism took steps this summer to underscore its support for translational research with new plans for a division dedicated to developing drugs for alcohol use disorder. According to...
07:00 , Aug 17, 2015 |  BioCentury  |  Finance

Medigene remade

Within 18 months, Medigene AG has used a small acquisition to gain a new, predominantly institutional shareholder base that has infused the German company with enough cash to pursue three platforms in parallel. Management says...
07:00 , Jul 1, 2013 |  BioCentury  |  Product Development

Antigen round up

Based on undisclosed data from an ongoing Phase I trial, Genentech Inc. decided to license rights to a 14-year-old technology that could allow the company to target a broad swath of cancer antigens that are...
07:00 , May 3, 2010 |  BioCentury  |  Emerging Company Profile

Adaptimmune: Evasion is futile

Adaptimmune Ltd. believes its autologous T cell therapies with high affinity T cell receptors can treat diseases that would otherwise evade the immune system. Its lead programs are for cancer and HIV. T cells are...
07:00 , Mar 9, 2009 |  BioCentury  |  Emerging Company Profile

Immunocore: Affinity for effective killing

Immunocore Ltd. is looking to breathe new life into a program that got its start 10 years ago inside Avidex Ltd. , which was spun out of the Institute of Molecular Medicine at the University...
08:00 , Dec 11, 2008 |  BC Innovations  |  Targets & Mechanisms

Ad out

When Merck & Co Inc. 's V520 HIV vaccine failed in last year's Phase II STEP trial, it was the most advanced T cell-based HIV vaccine in development. Two research teams now have posited different...
07:00 , Oct 6, 2008 |  BC Week In Review  |  Company News

MediGene cancer, autoimmune news

MediGene spun out Immunocore Ltd. (Abingdon, U.K.) to develop a monoclonal T cell receptor (mTCR) discovery program for cancer and autoimmune diseases. The newco raised £7 million ($12.7 million) in a series A round from...
07:00 , Oct 6, 2008 |  BioCentury  |  Finance

Ebb & Flow

Symphony Capital went bottom fishing and came up last week with OxiGene . The deal could provide up to $40 million for OxiGene and a newco set up to develop two of the biotech's compounds...
01:17 , Oct 2, 2008 |  BC Extra  |  Company News

MediGene spins out Immunocore

MediGene (Xetra:MDG) spun out Immunocore (Abingdon, U.K.) to develop a discovery-stage monoclonal T cell receptor (mTCR) program for cancer and autoimmune diseases. The newco raised L7 million ($12.7 million) in a series A round from...
08:00 , Jan 14, 2008 |  BC Week In Review  |  Company News

MediGene cancer, autoimmune, infectious news

MediGene said it is looking at alternative financing options for its MediGene Ltd. subsidiary's monoclonal T cell receptor (mTCR) research program, including potentially spinning the program out. The program has multiple candidates in research and...